Mersana Therapeutics Statistics
Share Statistics
Mersana Therapeutics has 124.63M
shares outstanding. The number of shares has increased by 1.86%
in one year.
| Shares Outstanding | 124.63M |
| Shares Change (YoY) | 1.86% |
| Shares Change (QoQ) | 0.89% |
| Owned by Institutions (%) | 84.98% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 10.53M, so 8.45% of the outstanding
shares have been sold short.
| Short Interest | 10.53M |
| Short % of Shares Out | 8.45% |
| Short % of Float | 9.23% |
| Short Ratio (days to cover) | 4.49 |
Valuation Ratios
The PE ratio is -2.53 and the forward
PE ratio is -0.46.
Mersana Therapeutics's PEG ratio is
0.04.
| PE Ratio | -2.53 |
| Forward PE | -0.46 |
| PS Ratio | 4.33 |
| Forward PS | 0.2 |
| PB Ratio | -18.43 |
| P/FCF Ratio | -2.12 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Mersana Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.19,
with a Debt / Equity ratio of -3.01.
| Current Ratio | 2.19 |
| Quick Ratio | 2.19 |
| Debt / Equity | -3.01 |
| Debt / EBITDA | -0.45 |
| Debt / FCF | -0.35 |
| Interest Coverage | -18.93 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $397,029.41 |
| Profits Per Employee | $-678,352.94 |
| Employee Count | 102 |
| Asset Turnover | 0.28 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 418K |
| Effective Tax Rate | -0.61% |
Stock Price Statistics
The stock price has increased by -86.26% in the
last 52 weeks. The beta is 1.3, so Mersana Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.3 |
| 52-Week Price Change | -86.26% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 48.95 |
| Average Volume (20 Days) | 3,088,047 |
Income Statement
In the last 12 months, Mersana Therapeutics had revenue of 40.5M
and earned -69.19M
in profits. Earnings per share was -0.56.
| Revenue | 40.5M |
| Gross Profit | 38.87M |
| Operating Income | -73.34M |
| Net Income | -69.19M |
| EBITDA | -63.27M |
| EBIT | -64.9M |
| Earnings Per Share (EPS) | -0.56 |
Full Income StatementBalance Sheet
The company has 107.75M in cash and 28.6M in
debt, giving a net cash position of 79.15M.
| Cash & Cash Equivalents | 107.75M |
| Total Debt | 28.6M |
| Net Cash | 79.15M |
| Retained Earnings | -895.55M |
| Total Assets | 144.66M |
| Working Capital | 74.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -82.34M
and capital expenditures -132K, giving a free cash flow of -82.47M.
| Operating Cash Flow | -82.34M |
| Capital Expenditures | -132K |
| Free Cash Flow | -82.47M |
| FCF Per Share | -0.67 |
Full Cash Flow StatementMargins
Gross margin is 95.98%, with operating and profit margins of -181.09% and -170.86%.
| Gross Margin | 95.98% |
| Operating Margin | -181.09% |
| Pretax Margin | -169.82% |
| Profit Margin | -170.86% |
| EBITDA Margin | -156.24% |
| EBIT Margin | -181.09% |
| FCF Margin | -203.65% |
